Skip to main content

Table 2 EGFR and K-Ras mutational status

From: EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition

 

Descriptive cohort (n = 103)

Correlative cohort (n = 66)

Anti-EGFR treated (n = 39)

 

n

%

n

%

n

%

EGFR mutational status

      

  Wild-type

72

70

47

71

24

62

  Mutant

31

30

19

29

15

38

Sites of EGFR mutation

      

  Exon 19 deletion

24

77*

14

74*

12

80*

E746_A750del

19

62*

10

54*

8

52*

E746_R748del

1

3*

1

5*

-

-

E746_E749 > Y

1

3*

1

5*

1

7*

L747_A750>P

1

3*

1

5*

1

7*

L747_T751del

1

3*

1

5*

1

7*

S751_I759del

1

3*

-

-

1

7*

  Exon 20 mutation

3

10*

2

10*

-

-

G796D

2

7*

1

5*

-

-

A767_V769dup

1

3*

1

5*

-

-

  Exon 21 mutation

4

13*

3

16*

3

20*

L858R

4

13*

3

16*

3

20*

K-Ras mutational status

      

  Wild-type

76

73

46

70

30

77

  Mutant

13

13

9

14

4

10

  Not evaluable

14

14

11

16

5

13

Sites of K-Ras mutation

      

  Codon 12 mutation

10

77*

7

78*

4

100*

G12C

6

46*

4

44*

3

75*

G12D

1

8*

-

-

-

-

G12V

3

23*

3

34*

1

25*

  Codon 13 mutation

3

23*

2

22*

-

-

G13D

3

23*

2

22*

-

-

  1. *Calculated as % of total EGFR and K-Ras mutations in each patient cohort.